Using cutoff values of 40% and 25% for tumor areas with 2+/3+ IHC staining intensity, CLDN18.2 expression was observed in 65 (56.0%) and 69 patients (59.5%), respectively. This evidence concerns the gene CLDN18 and neoplasm.